TakeQ4 FY19

Take Q4 FY19 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹12.62P/E: 21.4Market Cap: ₹187 CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 2
  • Company achieved a revenue of Rs. 2,039 Cr in FY2019, a 28.5% YoY growth in rupee terms and 19% in dollar terms, indicating strong growth momentum (Page 3).
  • Order book for Life Sciences as of March 2019 stood at $245.12 million, up 36.6% YoY, reflecting robust sales pipeline (Page 4).
  • Company expects continued strong growth aided by expansion in North America through recent acquisitions, enhancing full-service CRO capabilities (Page 8).
  • Growth driven by differentiated technology platforms like OneClinical, expanded predictive modeling, workflow enablement, and expanded services across therapeutic areas (Pages 7-8).
  • Expects to maintain EBITDA margins with some improvement from offshore delivery and operational efficiencies (Pages 14-15).
  • Anticipates steady-state unbilled receivables around 15 days; working capital cycle expected to improve from ~120-130 days to about 90 days over two years (Page 17).
  • Growth supported by continuing investments in IP, technology, and sales enablement assets (Pages 7, 15).

See what Take management said on margin guidance — free account, 30 seconds.

Fundraise plans

  • TAKE Solutions currently has credit lines available to support growth for the next several quarters.
  • They have maintained options to raise credit but have not specified any immediate new fundraises.
  • The acquisition of $52 million for DataCeutics and KAI Research was funded out of internal accruals and previous capital infusion.
  • The company currently holds a limited war chest of cash but has access to credit lines if needed.
  • No explicit mention of plans for fresh equity fundraising or additional debt issuance was made for the near term.
  • The focus appears to be on utilizing existing resources and credit facilities to support ongoing business and acquisitions.

See what Take management said on order book — free account, 30 seconds.

Capex plans

Yes
  • Internal capex requirements for FY2020 and FY2021 are generally manageable; the company feels fairly okay with current plans.
  • Several work-in-progress intellectual properties (IPs) are at an interesting stage, expected to be capitalized and go to market soon.
  • DataCeutics (DC) may not require much capex.
  • KAI Research (KAI) is expected to require some investment; originally planned in the budget.
  • Investment in KAI capex is anticipated to begin in one to two quarters from the discussion date (May 2019), not immediately.
  • Overall, FY2020 capex is expected to be between Rs.120 Crores to Rs.150 Crores or possibly less.

Track Take — get its next earnings analysis in your feed

How does Take rank vs peers in Healthcare Services?

Pro feature
ThisTake
Rev 2Mar 3

How does Take rank in Healthcare Services?

Compare Take against every Healthcare Services company (Q4 FY19) on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

Others in Healthcare Services this season

  • Chandan Healthca (Q2 FY27)

    Q2 FY27 operating income: ₹57.94 Cr, up 45.04% YoY from ₹39.95 Cr (Page 8) . Key investor presentation takeaways from Chandan Healthcare Ltd's Q2 FY27 investor

  • Invicta Diagnostic (Q2 FY27)

    Revenue from operations for the half year ended September 30, 2026: ₹379.11 lakhs (Page 4). Key results statement takeaways from Invicta Diagnostic Ltd's Q2 FY2

  • Unihealth Hosp (Q2 FY27)

    1,270 million with a year-on-year (YoY) growth of 6.3% . Key results statement takeaways from Unihealth Hospitals Ltd's Q2 FY27 results statement — and how it r

  • Sangani Hospital (Q2 FY27)

    1008.56 lakhs (~11.8% increase). Key results statement takeaways from Sangani Hospitals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →